# S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

> **NCT00053833** · PHASE2 · TERMINATED · sponsor: **SWOG Cancer Research Network** · enrollment: 2 (actual)

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Primary Peritoneal Cavity Cancer

## Interventions

- **DRUG:** irinotecan

## Key facts

- **NCT ID:** NCT00053833
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-04
- **Primary completion:** 2004-07
- **Final completion:** 2004-07
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** lack of accrual
- **Last updated:** 2013-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00053833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00053833, "S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00053833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*